GBS is a biosensor diagnostic technology company. Co.'s products are: Biosensor Platform Technology, which the Saliva Glucose Biosensor (SGB) is based is a modified Organic Thin Film Transistor; Saliva Glucose Test, which consists of the SGB, which is a single use disposable saliva biosensor, and software app on a smart device or a dedicated reader that interfaces the SGB with its digital information system; and SGB, which has the sensitivity of the glucose biosensor that enables it to detect glucose in saliva at concentrations and exhibits linear glucose sensing characteristics at these concentrations, sensing glucose at levels 100 times lower than in blood. The GBS average annual return since 2020 is shown above.
The Average Annual Return on the GBS average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether GBS average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the GBS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|